羚锐制药(600285.SH)发布上半年业绩，归母净利润4.74亿元，同比增长14.85%

Core Viewpoint - Lingrui Pharmaceutical (600285.SH) reported a revenue of 2.099 billion yuan for the first half of 2025, reflecting a year-on-year growth of 10.14% [1] - The net profit attributable to shareholders reached 474 million yuan, marking a year-on-year increase of 14.85% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 442 million yuan, up by 12.28% year-on-year [1] - Basic earnings per share stood at 0.836 yuan [1] Financial Performance - Revenue for the reporting period: 2.099 billion yuan, up 10.14% year-on-year [1] - Net profit attributable to shareholders: 474 million yuan, up 14.85% year-on-year [1] - Net profit after deducting non-recurring gains and losses: 442 million yuan, up 12.28% year-on-year [1] - Basic earnings per share: 0.836 yuan [1]